Diseased protein degrader shows mixed results in breast cancer trial

And the numbers that tell a scary story about the state of biotech

March 11, 2025 Check out STAT+

Sponsored By

Exclusive offer: Have your finger on the pulse of the biotech, pharma, and life science industries with a STAT+ subscription. Get 50% off your first year now.

Damian Dovarganes/AP STAT+ | Diseased protein degrader shows mixed results in breast cancer trial Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression more than 40% for an ESR1-mutated population, but not for a broader group. By Adam Feuerstein Scientists' suit against top academic publishers lays bare deep frustration over unpaid peer review Scientists want pay for peer review, freedom to submit to multiple journals. Publishers say their practices have been common for decades By Jonathan Wosen Bristol buys out cancer cell therapy partner Today's biotech news includes a struggling CAR-T partner 2Seventy Bio buyout, investors yet again disappointed by Novo data, and more. By Elaine Chen Molly Ferguson/STAT STAT+ | The numbers that tell a scary story about the state of biotech In this week's edition of "Adam's Biotech Scorecard," we take a closer look at small-cap biotechs, which are down 17%, on average, over three months. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser